We found that DNMT3a expression was significantly reduced by DAC treatment in U937, HL60, and Kasumi-1 cell lines, but not in the THP-1 cell line (Fig. 1G), indicating a differential susceptibility of AML subclones to DAC treatment among these cells. This evidence concerns the gene DNMT3A and acute myeloid leukemia.